Abstract 16237: Predicting Long-term Prognosis in Stable Peripheral Artery Disease With Baseline Functional Capacity Estimated by the Duke Activity Status Index
Introduction: The ability of a simple self-assessment tool for estimated functional capacity to predict long-term prognosis in patients with established peripheral artery disease (PAD) is unknown.
Objective: This study examined whether subjective measurement of functional capacity estimated by using of the Duke Activity Status Index (DASI) questionnaire predicts long-term prognosis in patients with established PAD.
Methods: We examined the relationship between DASI scores and all-cause mortality over a 5-year follow-up in 771 stable patients with established PAD.
Results: Two hundred ten patients (27%) died over 5-year follow-up . The lowest DASI scores were associated with a 3.2-fold increased risk of 5-year all-cause mortality (HR 3.23, 95%CI 2.19-4.75, p<0.001; Figure). For overall PAD patients, after adjustments for traditional risk factors, estimated glomerular filtration rate (eGFR), high-sensitivity C-reactive protein (hsCRP), and low DASI score remained predictive of 5-year all-cause mortality (adjusted HR 2.09, 95%CI 1.36-3.23, p<0.001). Adjusting for traditional risk factors, eGFR and hsCRP, patients with the lowest DASI scores had higher 5-year all-cause mortality (HR 2.13, 95%CI 1.1-4.12, p<0.05 for carotid artery stenosis (CAS); HR 2.06, 95%CI 1.16-3.64, p<0.05 for non-CAS; HR 2.01, 95%CI 1.11-3.66, p<0.05 for lower extremity artery stenosis (LEAD); and HR 2.15, 95%CI 1.13-4.09, p<0.005 for non-LEAD, respectively).
Conclusions: A simple self-assessment tool of functional capacity provides independent and incremental prognostic for long-term adverse clinical events in stable patients with established PAD beyond each PAD diagnostic subtype.
Author Disclosures: V. Senthong: None. Y. Wu: None. S. Hazen: Research Grant; Modest; Abbott, Cleveland Heart Lab, Liposcience Inc., P&G, Pfizer Inc., and Takeda.. Honoraria; Modest; cardiovascular diagnostics or therapeutics from the companies shown below: Abbott Laboratories, Inc., Cleveland Heart Lab., Siemens, Esperion, Frantz Biomarkers, LLC, Liposcience Inc. and P&G.. Consultant/Advisory Board; Modest; Abbott Laboratories, Cleveland Heart Lab, Esperion, Lilly, Liposcience Inc., Merck & Co., Inc., P&G, and Pfizer Inc. W. Tang: Research Grant; Significant; National Institutes of Health.
- © 2015 by American Heart Association, Inc.